This presentation explores the use of a high cell density cryopreservation (HCDC) method that utilizes bag assemblies specifically designed for freezing cells at higher densities and larger volumes, enabling them to directly inoculate the N-2 bioreactor. The integration of a perfused N-1 step in the upstream process is highlighted to either decrease facility footprint or to inoculate final fed-batch N-stage with a higher cell density than a conventional fed-batch. This streamlined method of initiating cell expansion can reduce the number of intermediate cell culture unit operations, allowing for a shortened expansion process by 10 days and to decrease the runtime of the final N-stage bioreactor.
In this webinar, you will learn about:
- Receiving an overview of intensified upstream processing
- How the HCDC process employs a closed single-use system, significantly reducing contamination risk and improving reproducibility
- How using a perfused N-1 step can either decrease your facility footprint or increase your biomass generation in your seed train
Speaker
Chris Kornfeld
Merck
Technical Consultant, Upstream Manufacturing Sciences and Technology
Chris Kornfeld has more than 11 years of experience in the biopharmaceutical industry and is currently part of our company's MSAT team as an upstream technical consultant. He has held various positions in his career, starting as a scientist in upstream R&D, a project manager, and, most recently, as a field application specialist. Through proactive technical collaboration, Chris enables our customers to remove roadblocks from their upstream processes so they can drive their programs forward. He holds a bachelor's degree in biology and psychology from St. Louis University and an economics degree from Washington University.
Pharma and biopharma manufacturing
- Viral Vector Upstream Processing
Duration:1h
Language:English
Session 1:presented September 15, 2022
To continue reading please sign in or create an account.
Don't Have An Account?